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ABSTRACT
Background: Hepatorenal syndrome type II and acute kidney injury found in
20% of cirrhotic patients. Rifaximin was found to reduce the frequency of
hepatorenal syndrome type II and acute kidney injury in alcohol cirrhotic
patients. This study aimed to evaluate the efficacy of rifaximin in prevention
of hepatorenal syndrome type II and acute kidney injury in Egyptian HCV
cirrhotic patients.
Methods: The study included 120 patients with decompensated post HCV
cirrhosis selected from patients admitted to Tropical Medicine department and
intensive care unit and from patients admitted to Internal Medicine department
and intensive care unit. They were classified into two groups the first was a
control group (n = 60) and the second was the rifaximin group (n = 60).
Rifaximin group patients were administered rifaximin tablet 550 mg twice
daily for 12 weeks. All patients were revaluated every 4 weeks and followed
up for 12 weeks in Tropical Medicine outpatient clinic and Internal Medicine
outpatient clinic.
Results: The incidence rate ratio of acute kidney injury (IRR 0.7 [95 % CI
0.53-0.92]) and hepatorenal syndrome type II (IRR 0.21 [95 % CI 0.06–0.70])
was statistically lower in the rifaximin group than the control group. The
estimated mean change in the control group was higher than the rifaximin
group in blood urea nitrogen [18.93(17.34-20.52) vs. 16.145(13.09-19.2)
mg/dl; P= 0.029] and serum creatinine [1.0525(0.9425-1.1625) vs.
0.995(0.885-1.105) mg/dl; P= 0.038].
Conclusion: Use of rifaximin is associated with decreased incidence of
hepatorenal syndrome type II and acute kidney injury in Egyptian HCV
cirrhotic patients.
Keywords: Rifaximin, hepatorenal syndrome type II, acute kidney injury,
cirrhosis.

ABSTRACT
enal dysfunction as acute kidney injury
(AKI) and hepatorenal syndrome (HRS)
type II found in 20% of cirrhotic patients.
HRS type II was identified by elevation of
serum creatinine more than 1.5 mg/dl, without
improvement in serum creatinine after at least
2 days with withdrawal of diuretic and
volume expansion with fluids or albumin.
HRS type II is accompanied by hypotension
and dilutional hyponatremia. The mechanism
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of HRS type II may result from spontaneous
bacterial
peritonitis
(SBP)
through
translocation of bacteria, systemic and
splanchnic arterial vasodilatation, altered
renal physiologic autoregulation, adrenal
insufficiency, and cardiac dysfunction [1].
AKI was defined as an increase in serum
creatinine by 0.3 mg/dl within 48 hours or
increase in serum creatinine to >1.5 times
baseline, which is known or presumed to
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have occurred within the prior 7 days; or
urine volume < 0.5 ml/kg/h for 6 hours [2].
Rifaximin is an oral antibiotic that poorly
absorbed from the gastrointestinal tract. It has
broad-spectrum in vitro activity with a low
risk of developing bacterial resistance [3]. It
is a potent drug in the prophylaxis and
treatment of hepatic encephalopathy [4],
which has been the center point of its
research. Overgrowth of bacteria in cirrhotic
patients is accompanied by increased levels of
endotoxins and cytokines as interleukin-6 (IL6) and tumor necrosis factor-α (TNF-α) which
is accompanied by decreased systemic
vascular resistance and increased risk of
developing renal injury and death [13].
Rifaximin decreased circulating levels of
TNF-a and enhanced hemodynamic by an
increase in systemic vascular resistance and
glomerular filtration rate and decrease in
portal vascular resistance [4]. Studies on
alcohol cirrhotic patients, rifaximin reduced
the frequency of HRS type II and AKI [5].
This study aimed to determine the efficacy
and outcomes of rifaximin in prevention of
hepatorenal syndrome type II and acute
kidney injury in Egyptian HCV cirrhotic
patients.
METHODS
Informed consent and ethics committee/IRB
approval:
The study protocol was approved from the
Institutional Research Board committee at
Faculty of Medicine, Zagazig University. The
study was conducted according to the clinical
practice guidelines and according to the Code
of Ethics of the World Medical Association
(Declaration of Helsinki) for studies involving
humans. A written informed consent was
obtained from every patient.
Study design:
A hospital-based non-interventional clinical
trial was carried out in the Tropical Medicine
department and intensive care unit and
Internal Medicine department and intensive
care unit Zagazig University, in the period
from February 2019 and October 2020. All
official permissions were obtained from the
managers of the Tropical Medicine
department,
Zagazig
University.
The
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objectives of this study were explained to
them to ensure their cooperation.
Patients’ selection and data collection:
The sample size was calculated according to
the expected positive predictive value of 70,
power of the study 85%, and 95% confidence
interval using EPI info 6. It included 120
Egyptian patients with decompensated HCV
cirrhosis which was diagnosed by HCVab and
polymerase chain reaction (PCR). They were
selected from patients admitted to Tropical
Medicine department and intensive care unit
and also from patients admitted to Internal
Medicine department and intensive care unit.
They were classified into two groups. The
first group was a control group (60) and the
second group was the rifaximin group (60).
The exclusion criteria were patients younger
than 18 years old, patients who refused to
give consent, patients with hepatocellular
carcinoma or cholangiocarcinoma, patients
with nephropathy, or on nephrotoxic drugs or
patients with HRS type II. Patients with SBP
must be excluded by ascitic fluid analysis.
Sepsis had to be excluded (chest x-ray to
exclude chest infection and pneumonia,
complete blood count (CBC) to exclude any
systemic infection and urine examination to
exclude urinary tract infection and any renal
abnormality such as proteinuria or casts).
Rifaximin group patients were administered a
rifaximin tablet 550 mg twice daily for 12
weeks. On admission all patients underwent
thorough
full
history,
full
clinical
examination, CBC,
liver function tests,
kidney function tests, INR, sodium,
potassium, ascitic fluid analysis for exclusion
of other causes of ascites and spontaneous
bacterial peritonitis
and pelviabdominal
ultrasound. Patients were followed up for 12
weeks in Tropical Medicine outpatient clinic
and Internal Medicine outpatient clinic.
Every 4 weeks renal functions, CBC, LFTs,
pelviabdominal ultrasound and diagnostic
paracentesis were done. Patients were
monitored for HRS type II and AKI. HRS
type II was diagnosed by serum creatinine
more than 1.5 mg/dl, without improvement in
serum creatinine after at least 2 days with
withdrawal of diuretic and volume expansion
with fluids or albumin. AKI was defined as an
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increase in serum creatinine by 0.3 mg/dl
within 48 hours increase in serum creatinine
to >1.5 times baseline, which is known or
presumed to have occurred within the
prior 7 days; or urine volume < 0.5 ml/kg/h
for 6 hours.
Data analysis
Data were analyzed statistically using IBM
SPSS Statistics, version 21 for Windows
(IBM Corporation, North Castle Drive,
Armonk, New York, USA). Data are
expressed as mean±SD. All P values are twotailed, with values less than 0.05 considered
statistically significant. Comparisons between
two groups were performed using Student’s ttest for parametric data and the Mann–
Whitney test for nonparametric data. χ2 and
Fisher’s exact test was used for categorical
data analysis. Repeated-measures analysis of
variance test was used for serial variables.
Frequency is expressed as an incidence rate
ratio (IRR) with 95 % confidence interval (95
% CI) and was calculated using a Poisson
regression model. A p-value <0.05 was
considered statistically significant.
RESULTS
Table 1 exhibits the baseline data. There are
no significant differences regarding age, sex,
virology, liver function tests, INR, Child
score, and potassium. Patients in the control
group have a statistically significantly lower
serum sodium level (130.82±3.1 vs.
132.9±2.9 mmol/l; P=0.04).
Table 2 exhibits the effect of rifaximin on the
incidence rate of multiple variables. Thirtyseven patients in the control group had a total
of 73 AKI episodes during the follow-up
period, while 31 patients in the rifaximin
group had a total of 61 AKI episodes.
Thirteen patients in the control group had a
total of 14 HRS type II episodes, while 3
patients in the rifaximin group had a total of 3
HRS type II episodes. The incidence rate
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ratios of HRS type II (IRR 0.21 [95 % CI
0.06–0.70]) and AKI (IRR 0.7 [95 % CI 0.530.92]) are statistically lower in the rifaximin
group than the control group, there is a high
statistically significant difference between the
groups regarding HRS type II and AKI. 26
patients in the control group developed (SBP),
while only two patient in the rifaximin group
developed (SBP) with highly significant
difference.
Table 3 exhibits the impact of rifaximin on
the serial renal functions (weeks 0 through
12). There is a statistically significant
difference in the serial blood urea nitrogen
(BUN) readings in the control group
(16.9±5.3, 16.7±8.2, 19.2±6.8 and 22.92±6.3
mg/dl; P=0.008) in contrast to the rifaximin
group (14.8±5.4, 16.6±5.4, 17.8±4.2 and
15.38±4.6 mg/dl; P=0.169). The BUN values
are statistically higher in the control group
than the rifaximin group in week 4
(16.7±8.2vs. 16.6±5.4 mg/dl), week 8
(19.2±6.8vs. 17.8±4.2 mg/dl), and week 12
(22.92±6.3 vs.15.38±4.6 mg/dl). There is a
statistically significant difference in the serial
serum creatinine readings in the control group
(0.88±0.26, 0.98±0.27, 1.16±0.12 and
1.19±0.2 mg/dl; P=0.006) in contrast to the
rifaximin group (0.96±0.17, 0.95±0.25,
1.08±0.11 and 0.99±0.18 mg/dl; P=0.139).
The serum creatinine values are statistically
higher in the control group than the rifaximin
group in week 4 (0.98±0.27 vs. 0.95±0.25
mg/dl), and week 12 (1.19±0.2 vs. 0.99±0.18
mg/dl). The estimated mean change in the
control group is higher than the rifaximin
group in BUN [18.93(17.34-20.52) vs.
16.145(13.09-19.2) mg/dl; P= 0.029] and
serum creatinine [1.0525(0.9425-1.1625) vs.
0.995(0.885-1.105) mg/dl; P= 0.038],
reinforcing the potential preventive effect of
rifaximin in renal insult.
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Table (1) Baseline data for both groups:

Age (Mean ±SD) (years)
Sex
-Female

-Male

Bilirubin (mg/dl)
Albumin (g/dl)
AST (U/l)
ALT (U/l)
Child score
Child class
- Child B
- Child C

INR
Potassium (mmol/l)
Sodium (mmol/l)

Control group (60)

Rifaximin group (60)

56.3±8.2

58.5±4.8

33 (55 %)
27 (45 %)

36 (60 %)
24 (40 %)

2.62±1.9
2.25±0.5
64.21±29.02
40.2±23.2
10.1±0.9

2.4±1.51
2.6±0.2
65.43±32.8
35.3±16.8
11.5±1.6

19 (31.6 %)
41 (68.4 %)

21 (35 %)
39 (65 %)

1.68 ±0.6
3.5 ±0.88
130.82 ±3.1

P value
0.18
0.39

160 (MW)
0.31
0.243
0.395 (MW)
0.324
0.513

1.59 ±0.51
3.65 ±0.79
132.9 ±2.9

0.59
0.492
0.04 (S)

MW=Mann Whitney
Table 2 exhibits effect of rifaximin on incidence rate of multiple variables:

AKI
HRS
Hepatic
encephalopathy
Paracentesis
Variceal
bleeding
Spontaneous
bacterial
peritonitis

Control
group
incidence
ratio
per 3 months
3.68
0.62
0.73

Rifaximin
group
incidence
ratio
per 3 months
1.39
0.071
0.84

0.81
0.17

1.19
0.07

1.82

0.64
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Rifaximin group
as compared
to control
(incidence rate
ratio)
0.7
0.21
1.14

95 % CI
of
Incidence
rate ratio

P value

0.53-0.92
0.06-0.7
0.91-1.29

<0.001(HS)
<0.001(HS)
0.2

1.43
0.48

0.75-2.62
0.09-2.5

0.24
0.34

0.41

0.45-0.78

<0.001(HS)
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Table 3 exhibits sequential renal function analysis:
BUN
Weeks

Control
group

Creatinine

1

16.9±5.3

Rifaximi
n
group
14.8±5.4

4

16.7±8.2

16.6±5.4

0.01

0.98±0.27

8

19.2±6.8

17.8±4.2

0.009
(MW)

1.16±0.12

1.08±0.11

0.21
(MW)

12

22.92±6.3

15.38±4.
6

0.008
(MW)

1.19±0.2

0.99±0.18

0.04

P

0.008

0.169

-

0.006

0.139

-

Estimated overall
mean (95%
confidence
interval)

18.9
(17.3420.52)

16.145
(13.0919.2)

-

1.0525
(0.94251.1625)

0.995
(0.8851.105)

-

P

0.029

MW=Mann Whitney
DISCUSSION
Cirrhotic patients are susceptible to bacterial
overgrowth, intestinal dysmotility, and
increased bacteria translocation [6]. Bacterial
infections are considered one of most
important precipitating factors in development
of HRS and AKI. The most serious bacterial
infection is (SBP).The most common cause of
SBP is E.coli which is derived from the gut
together with bacterial overgrowth. So
intestinal decontamination is very important in
preventing HRS type II and AKI in cirrhotic
patients. Specific intestinal decontamination
with norfloxacin in alcoholic cirrhotic patients
improved vascular tone by relatively inverting
the chronic portal and systemic vasodilation
present in alcoholic cirrhotic [7]. Likewise,
Fernandez et al. revealed that norfloxacin
diminished the occurrence of spontaneous
bacterial peritonitis (SBP) and postponed the
onset of HRS type II in 35 patients out of 68
patients with advanced cirrhosis [8].
Many antibiotics are used in gut
decontamination for treatment of hepatic
encephalopathy and prevention of SBP. One
of the most important of these antibiotics is
El-Gebaly A., et al
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P value

Control
group

0.692

0.88±0.26

Rifaximi
P value
n
group
0.96±0.17 0.951(MW
)
0.95±0.25
0.049
(MW)

0.038
rifaximin which had lowest side effect and
high selectivity for gut pathogen and high gut
concentration because of poorly absorbed.
Rifaximin was more beneficial than
norfloxacin in prevention of SBP [9]. It was
utilized to treat hepatic encephalopathy [10],
and decrease hospital admission [3].
Rifaximin was beneficial for the primary
prevention of SBP whether used alone [11] or
in addition to norfloxacin [12]. In patients
with alcoholic hepatitis, prognosis as well as
the renal functions and hemodynamic were
enhanced with rifaximin therapy [4], [5].
Cirrhotic patients with bacterial translocation
and endotoxemia manifest hemodynamic
disturbance, decreased systemic vascular
resistance, higher cardiac output, and
hypotension. This overgrowth of bacteria is
accompanied by increased levels of
endotoxins and cytokines such as interleukin6 (IL-6) and tumor necrosis factor-α (TNF-α)
which in turn is accompanied by an increased
risk of developing renal injury and death [13].
A study done by Kalambokis et al. showed
that rifaximin decreased circulating levels of
TNF-a and enhanced hemodynamic by an
564 | P a g e
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increase in systemic vascular resistance and
glomerular filtration rate [4]. Also, endotoxins
increase portal vascular resistance by the
release of endothelin and cyclooxygenase
products [13].
Recently, a randomized clinical trial made by
Kimer et al. denied the hemodynamic effect
of rifaximin. He assessed the impact of 4
weeks of rifaximin on 36 alcoholic cirrhotic
patients. On follow-up, rifaximin had no
impact on the systemic and portal vascular
resistance, glomerular filtration rate, blood
pressure, and cardiac output. It only decreased
bacterial translocation as measured by
lipopolysaccharide-binding protein [14], but a
small number of patients and alcohol as the
only cause of cirrhosis made this result
doubtful.
In our study, rifaximin group of patients had
more stable renal functions with fewer
episodes of renal dysfunction over the 12week treatment period compared with the
control group. Also, they had the lowest
incidence of HRS type II and AKI. This is
mainly due to the effect of rifaximin in
decreasing bacterial translocation and the
incidence of SBP. Also due to its role in
increasing in systemic vascular resistance
and glomerular filtration rate and decreasing
portal vascular resistance by its inhibitory
effect of bacterial overgrowth and cytokines
release[4, 13].This was in agreement with
Dong et al. who investigated the long-term
impact of rifaximin on the renal functions in
cirrhotic patients and he found that patients
used rifaximin for at least 90 days had lower
frequency of AKI, HRS type II, and the
demand for renal replacement therapy. Most
patients in his study were mainly alcoholic,
but in our study, all patients were hepatitis c
virus (HCV) cirrhotic patients [15]. There
were no significant differences regarding
encephalopathy, need for paracentesis and
variceal bleeding,
In our study the main limitation is the small
number of patients and the cause of cirrhosis
in all patients was HCV. Conducting future
studies examining the role of rifaximin in
decreasing incidence of hepatorenal syndrome
type II and acute kidney injury in different
liver disease is highly recommended. Finally,
El-Gebaly A., et al
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the association between the use of rifaximin
with incidence of hepatorenal syndrome type
II and acute kidney injury in cirrhotic patients
should be addressed through prospective
studies.
Conclusion
Use of rifaximin is associated with decreased
incidence of hepatorenal syndrome type II
and acute kidney injury in Egyptian HCV
cirrhotic patients.
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